{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:23:42Z","timestamp":1790425422457,"version":"4.1.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Jena University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.rmcr.2022.101614","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T01:50:26Z","timestamp":1645494626000},"page":"101614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7104-9547","authenticated-orcid":false,"given":"Hortense","family":"Slevogt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10098","key":"10.1016\/j.rmcr.2022.101614_bib1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0140-6736(17)31448-4","article-title":"Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012)","volume":"390","author":"Ebmeier","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.rmcr.2022.101614_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.7326\/L18-0359","article-title":"Omalizumab rescue therapy for refractory status asthmaticus","volume":"170","author":"Milger","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.rmcr.2022.101614_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): innovate","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.rmcr.2022.101614_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.rmcr.2022.101614_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.yrtph.2014.12.002","article-title":"Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE","volume":"71","author":"Lowe","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007122000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007122000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:05:39Z","timestamp":1761959139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007122000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":5,"alternative-id":["S2213007122000363"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2022.101614","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2022.101614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101614"}}